Current treatments focus on controlling inflammation and minimizing long-term damage. Learn more.

Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis, or AAV, causes inflammation of the blood vessels and can affect many parts of the body, including multiple organs. Because of this, ...

Almost all AAV cases were diagnosed in individuals with high pretest probability, including those with renal disease, peripheral neuropathies, or pulmonary infiltrates.

Please provide your email address to receive an email when new articles are posted on . DESTIN, Fla. — Despite advances in biologic therapies, “excess steroid use” remains a mainstay of treatment for ...

-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- “The vasculitis community is elated that TAVNEOS is now approved, bringing a much-needed new treatment option to ...

Treatment of antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis and renal disease with the oral C5a receptor inhibitor avacopan (Tavneos, ChemoCentryx) provides significant recovery ...

Pulmonary involvement is highly prevalent in individuals with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), affecting 82.7% of patients with granulomatosis with polyangiitis ...

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), a clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, today ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Treatment with a fixed interval of either 500 mg or ...

Chronic lung disease is associated with a higher risk for infection in patients with ANCA-associated vasculitis during both induction and maintenance treatment.

DelveInsight's“ ANCA Vasculitis Pipeline Insight 2025” report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the ANCA Vasculitis pipeline landscape. It covers the ANCA ...

SAN CARLOS, Calif., Jan. 19, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that TAVNEOS® (avacopan) has been approved within the European Union in combination with a ...